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ABSTRACT

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the cause of Coronavirus Disease 2019 (COVID19) and responsible for the current pandemic. Recent SARS-CoV-2 susceptibility studies in cats show that the virus
can replicate in these companion animals and transmit to other cats. Here, we present an in-depth study of SARSCoV-2 infection, disease and transmission in domestic cats. Cats were challenged with SARS-CoV-2 via intranasal
and oral routes. One day post challenge (DPC), two sentinel cats were introduced. Animals were monitored for
clinical signs, clinicopathological abnormalities and viral shedding. Postmortem examinations were performed at
4, 7 and 21 DPC. Viral RNA was not detected in blood but transiently in nasal, oropharyngeal and rectal swabs
and bronchoalveolar lavage ﬂuid as well as various tissues. Tracheobronchoadenitis of submucosal glands with
the presence of viral RNA and antigen was observed in airways of the infected cats. Serology showed that
both, principals and sentinels, developed antibodies to SARS-CoV-2. All animals were clinically asymptomatic
during the course of the study and capable of transmitting SARS-CoV-2 to sentinels. The results of this study
are critical for understanding the clinical course of SARS-CoV-2 in a naturally susceptible host species, and for
risk assessment.
ARTICLE HISTORY Received 18 August 2020; Revised 2 October 2020; Accepted 5 October 2020
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Introduction
Coronaviruses are enveloped single-stranded, positive-sense RNA viruses that belong to the order Nidovirales in the family Coronaviridae, subfamily
Orthocoronavirinae, and are comprised of four genera:
Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and Deltacoronavirus [1]. The Severe Acute Respiratory Syndrome-related coronaviruses (SARS-CoV
and SARS-CoV-2), and the Middle East Respiratory
Syndrome coronavirus (MERS-CoV) belong to the
genus Betacoronavirus [2,3]. Alpha- and betacoronaviruses infect mammals and cause important respiratory, enteric, and systemic infectious diseases of
humans, cattle, pigs, cats, dogs, horses, and camels
[1,4,5]. Importantly, coronaviruses can occasionally
cross the species barriers [6,7].

Bats have been identiﬁed as a reservoir species for
zoonotic coronaviruses including those causing
important human epidemics, namely SARS-CoV in
2002–2003 and MERS-CoV since 2012 [6]. Camels
have since been shown to serve as the primary intermediate and reservoir host for MERS-CoV, causing
continued zoonotic animal-to-human transmissions
[8]. During the SARS-CoV epidemic, infected domestic cats were identiﬁed from households of SARSCoV positive patients, and both cats and ferrets were
subsequently experimentally shown to be easily
infected and to transmit SARS-CoV [9,10].
SARS-CoV-2 is the cause of Coronavirus Disease
2019 (COVID-19) and responsible for the current global pandemic [11]. A zoonotic transmission event
ampliﬁed at a seafood and animal market in Wuhan,
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Hubei Province, China, is suspected to be the site of
the ﬁrst signiﬁcant outbreak in humans [12], with
bats and/or pangolins being speculated as the potential
origin species based on the sequence homology of coronaviruses isolated from these animals [11,13,14].
Since the outbreak of SARS-CoV-2 was ﬁrst identiﬁed in December of 2019, it has been demonstrated
that SARS-CoV-2 can naturally and experimentally
infect several animal species [15–17]. There have
been multiple case reports of natural transmission of
the virus from COVID-19 patients to dogs and cats,
infection of “big cats” (i.e. a lion and tigers) at the
Bronx Zoo, and infection of mink on farms in The
Netherlands, Denmark, Spain, and the United States
[17–19]. In a recent animal susceptibility study,
dogs, cats, ferrets, pigs, chickens and ducks were
experimentally infected with SARS-CoV-2 [20]. The
results from that study show that both cats and ferrets
were eﬃciently infected and could transmit the virus,
dogs showed low susceptibility, while pigs and avian
species were non permissive hosts. In addition, nonhuman primates (NHPs), hamsters and hACE2 transgenic or adenovirus transduced mice have also been
evaluated as potential animal models for SARS-CoV2 and seem to be highly susceptible showing mild to
severe clinical signs [15,21].
The close association between humans and animals
including companion animals, livestock and wildlife
species, raises concerns regarding the potential risks of
transmission of SARS-CoV-2 from COVID-19 patients
to animals (“reverse zoonosis”), and the potential role
infected animals could play in perpetuating the spread
of the disease [16,19]. Therefore, further research of
SARS-CoV-2 infection in various animal species is
needed in order to identify susceptible hosts and to better understand the infection, disease, clinical course and
transmission capabilities of susceptible animal species.
This knowledge is important for risk assessment, implementing mitigation strategies, addressing animal welfare
issues, and to develop preclinical animal models for
evaluating drug and vaccine candidates for COVID-19.
Here, we present an in-depth study of SARS-CoV-2
infection, associated disease and transmission in domestic cats. Clinical evaluation of weight, body temperature, blood parameters, serology, viral RNA shedding
and RNA distribution in tissues and organ systems,
and associated pathological ﬁndings are presented
and discussed.

Material and methods
Cells and virus
Vero E6 cells (ATCC® CRL-1586™, American Type
Culture Collection, Manassas, VA, USA) were used
for virus propagation and titration. Cells were cultured in Dulbecco’s Modiﬁed Eagle’s Medium
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(DMEM, Corning, New York, N.Y, USA), supplemented with 5% fetal bovine serum (FBS, R&D Systems, Minneapolis, MN, USA) and antibiotics/
antimycotics (ThermoFisher Scientiﬁc, Waltham,
MA, USA), and maintained at 37°C under a 5% CO2
atmosphere. The SARS-CoV-2 USA-WA1/2020 strain
was acquired from BEI Resources (Manassas, VA,
USA) and passaged three times in Vero E6 cells to
establish a stock virus (1 × 106 TCID50/ml) for inoculation of animals. This stock virus was sequenced by
next generation sequencing (NGS) using the Illumina
MiSeq and its consensus sequence was found to be
100% homologous to the original USA-WA1/2020
strain (GenBank accession: MN985325.1). To determine infectious virus titre, 10-fold serial dilutions
were performed on Vero E6 cells. The presence of cytopathic eﬀects (CPE) after 96 h incubation was used to
calculate the 50% tissue culture infective dose (TCID50)/ml using the Spearman-Karber method [22].
Animals and experimental design
Ethics statement for use of animals
All animal studies and experiments were approved
and performed under the Kansas State University
(KSU) Institutional Biosafety Committee (IBC, Protocol #1460) and the Institutional Animal Care and Use
Committee (IACUC, Protocol #4390) in compliance
with the Animal Welfare Act. All animal and laboratory work were performed in biosafety level-3+ and
−3Ag laboratories and facilities in the Biosecurity
Research Institute at KSU in Manhattan, KS, USA.
Virus challenge of animals
Ten 4.5- to 5-month-old intact male cats were acclimated for seven days to BSL-3Ag biocontainment
prior to experimental procedures with feed and
water ad libitum. These were antibody proﬁle
deﬁned/speciﬁc pathogen free (APD/SPF) animals
with no detectable antibody titres to feline herpesvirus
(rhinotracheitis), feline calicivirus, feline panleukopenia virus, feline coronaviruses, feline immunodeﬁciency virus, Chlamydia felis and Toxoplasma gondii
obtained from Marshall BioResources (North Rose,
New York, USA). The cats were placed into three
groups (Figure 1). Group 1 (principal infected animals) consisted of six cats (three cats per housing
unit), and was inoculated simultaneously via the intranasal and oral routes with a total dose of 1 × 106
TCID50 of SARS-CoV-2 in a total volume of 2 ml
DMEM medium (0.5 ml per nostril and 1 ml oral).
The cats in Group 2 (n = 2; sentinel contact animals)
and Group 3 (n = 2; mock control animals) were
housed in a separate room (Figure 1). Mock-infected
cats (Group 3) were administered 2 ml DMEM via
the intranasal and oral routes similar to Group 1 animals. At 1-day post challenge (DPC), the two cats in
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Figure 1. Study design. Ten cats were placed into three groups. Group 1 (principal infected animals) consisted of six cats (three
cats/housing unit) and was inoculated via intranasal (IN) and oral (PO) routes simultaneously with a total dose of 1 × 106 TCID50 of
SARS-CoV-2 in 2 ml DMEM. The cats in Group 2 (n = 2; sentinel contact animals) and Group 3 (n = 2; mock control animals) were
housed in a separate room. At 1-day post challenge (DPC), the two cats in Group 2 were co-mingled with the principal infected
animals in Group 1 (one cat per cage) and served as sentinel contact controls. The remaining two cats in Group 3 were housed in a
separate room and served as mock-infected negative controls. Principal infected animals were euthanized and necropsied at 4 (n
= 2), 7 (n = 2) and 21 (n = 1) DPC to evaluate the course of disease. The two negative control animals in Group 3 were euthanized
and necropsied at 3 DPC. The remaining three animals from Group 1 (one principal infected animal) and Group 2 (two sentinel
contact animals) were maintained for future re-infection studies.

Group 2 were co-mingled with the principal infected
animals in Group 1 (one cat per housing unit), and
served as sentinel contact controls. The remaining
two cats in Group 3 remained housed in a separate
room and served as mock-infected negative controls.
Principal infected animals were euthanized for postmortem examinations at 4 (n = 2), 7 (n = 2) and 21
(n = 1) DPC to evaluate the course of disease. The
two negative control animals in Group 3 were euthanized for postmortem examinations at 3 DPC. The
remaining three animals from Group 1 (one principal
infected animal) and Group 2 (two sentinel contact
animals) were maintained for future re-infection
studies, and not terminated as part of this study.
Clinical evaluations and sample collection
Cats were observed daily for clinical signs, such as:
fever, anorexia, lethargy, respiratory distress, inappetence, depression, recumbency, coughing, sneezing, diarrhea/loose stool, vomiting and others.
Weights of all cats were recorded on bleed days.
Blood and serum were collected from all cats,
including sentinel contact controls, on −1 DPC
prior to infection, and on days 1, 3, 5, 7, 10, 14
and 21 DPC via venipuncture of the cephalic vein
under anesthesia or during terminal bleeding by
cardiac puncture. Nasal, oropharyngeal and rectal
swabs were also collected on −1, 1, 3, 5, 7, 10, 14
and 21 DPC in 2 ml of viral transport medium
(VTM; DMEM; Corning,) with antibiotics/antimycotic (ThermoFisher). Swabs were vortexed and
supernatant aliquoted directly into cryovials or

into RLT buﬀer (Qiagen, Germantown, MD, USA)
and stored at −80°C until further analysis.
A full postmortem examination was performed for
each cat at the indicated time-points and gross
changes (if any) were recorded. Tissues were collected
either in 10% neutral-buﬀered formalin (Fisher Scientiﬁc, Waltham, MA, USA), or as fresh tissues which
were then frozen at −80°C. A postmortem examination
protocol was developed to collect the upper and lower
respiratory tract, central nervous system (brain and
cerebral spinal ﬂuid [CSF]; Figure S1A), gastrointestinal (GI) tract as well as accessory organs. The lungs
were removed in toto including the trachea, and the
main bronchi were collected at the level of the bifurcation and at the entry point into the lung lobe (Figure
S1B). Lung lobes were evaluated based on gross pathology and collected and sampled separately (Figure
S1C). Bronchoalveolar lavage ﬂuid (BALF), nasal
wash and urine were also collected during postmortem
examination and stored at −80°C until analysed. Fresh
frozen tissue homogenates were prepared by thawing
tissue and placing 200 mg (± 50 mg) of minced tissue
in a tube containing 1 ml DMEM culture medium and
a steel bead (Qiagen). Homogenization was performed
with the TissueLyser LT (Qiagen) for 30 s at 30 hertz
and repeated 3 times. Supernatant was retained after
centrifugation for RNA extraction and reverse transcription quantitative PCR (RT-qPCR).
Blood cell counts
Complete blood cell counts were performed using
fresh EDTA blood samples run on an automated
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VetScan HM5 Hematology Analyser (Abaxis Inc.,
Union City, CA) according to the manufacturer’s recommended protocol using the VetScan HM5 reagent
pack and recommended calibration controls. Blood
cell analysis included: complete white blood cells, lymphocytes, monocytes, neutrophils, eosinophils, basophils, red blood cells, hematocrit, hemoglobin and
platelets.
Serum biochemistry
Serum chemistry was performed using an automated
VetScan VS2 Chemistry Analyser (Abaxis) according
to the manufacturer’s recommended protocol. The
Comprehensive Diagnostic Proﬁle reagent rotor was
used to perform complete chemistry and electrolyte
analysis on 14 blood components: alkaline phosphatase, creatine, globulin, phosphorous, glucose, blood
urea nitrogen, sodium, potassium, calcium, alanine
aminotransferase, amylase, albumin, total bilirubin,
total protein. Brieﬂy, 100 µl of serum was added to
the sample port of the reagent rotor, which was subsequently run in the machine.
RNA extraction and reverse transcription
quantitative PCR (RT-qPCR)
SARS-CoV-2-speciﬁc RNA was detected using a RTqPCR assay. Brieﬂy, tissue homogenates in DMEM,
blood, CSF, BALF, urine, and nasal, oropharyngeal
and rectal swabs in VTM were mixed with an equal
volume of RLT RNA stabilization/lysis buﬀer (Qiagen,
Germantown, MD, USA), and 200μl of sample lysate
was then used for extraction using a magnetic beadbased nucleic acid extraction kit (GeneReach USA,
Lexington, MA) on an automated TacoTM mini
nucleic acid extraction system (GeneReach) according
to the manufacturer’s protocol with the following
modiﬁcations: beads were added to the lysis buﬀer in
the ﬁrst well followed by the RLT sample lysate, then
by the addition of 200 μl molecular grade isopropanol
(ThermoFisher), and ﬁnally, the last wash buﬀer B was
replaced with 200 proof molecular grade ethanol
(ThermoFisher). Extraction positive controls (IDT,
IA, USA; 2019-nCoV_N_Positive Control, diluted
1:100 in RLT) and negative controls were employed.
Quantiﬁcation of SARS-CoV-2 RNA was performed using the N2 SARS-CoV-2 primer and probe
sets (see: https://www.idtdna.com/pages/landing/
coronavirus-research-reagents/cdc-assays) in a RTqPCR protocol established by the CDC for the detection of SARS-CoV-2 nucleoprotein (N)-speciﬁc RNA
(https://www.fda.gov/media/134922/download). This
protocol has been validated in our lab for research
use, using the qScript XLT One-Step RT-qPCR
Tough Mix (Quanta BioSsciences, Beverly, MA,
USA) on the CFX96 Real-Time thermocycler (BioRad,
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Hercules, CA, USA) using a 20-minute reverse transcription step and 45 cycle PCR in a 20 μl reaction
volume. A reference standard curve method using a
10-point standard curve of quantitated viral RNA
(USA-WA1/2020 isolate) was used to quantify RNA
copy number. RT-qPCR was performed in duplicate
wells with a quantitated PCR positive control (IDT,
IA, USA; 2019-nCoV_N_Positive Control, diluted
1:100) and four non-template control (NTC) on
every plate. A positive Ct cut-oﬀ of 40 cycles was
used. Data are presented as the mean and standard
deviation of the calculated N gene copy number per
ml of liquid sample or per mg of a 20% tissue
homogenate.
Virus neutralizing antibodies
Virus neutralizing antibodies in sera were determined
using microneutralization assay. Brieﬂy, serum
samples were initially diluted 1:10 and heat-inactivated at 56°C for 30 min while shaking. Subsequently,
100 μl per well of serum samples in duplicates were
subjected to 2-fold serial dilutions starting at 1:20
through 1:2560 in 100 μl culture media. Then, 100 μl
of 100 TCID50 of SARS-CoV-2 virus in DMEM culture media was added to 100 μl of the sera dilutions
and incubated for 1 h at 37°C. The 200 μl per well of
virus serum mixture was then cultured on Vero E6
cells in 96-well plates. The corresponding SARSCoV-2-negative cat serum, virus only and media
only controls were also included in the assay. The neutralizing antibody titre was recorded as the highest
serum dilution at which at least 50% of wells showed
virus neutralization (NT50) based on the appearance
of CPE observed under a microscope at 72 h post
infection.
Detection of SARS-CoV-2 antibodies by indirect
ELISA
To detect SARS-CoV-2 antibodies in sera, indirect
ELISAs were performed with the recombinant viral
proteins, nucleocapsid (N) and the receptor-binding
domain (RBD), which were produced in-house. The
N protein was produced in E. coli with a C-terminal
His-Tag, and the RBD was expressed in mammalian
cells with a C-terminal Strep-Tag; they were puriﬁed
using either Ni-NTA (ThermoFisher) or Strep-Tactin (IBA Lifesciences, Goettingen, Germany) columns, respectively, according to the manufacturers’
instructions.
For indirect ELISAs, wells were coated with 100 ng
of the respective protein in 100 μl per well coating
buﬀer (Carbonate–bicarbonate buﬀer, catalogue number C3041, Sigma-Aldrich, St. Louis, MO, USA), then
covered and incubated overnight at 4°C. The next day,
the plates were washed two times with phosphate
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buﬀered saline (PBS [pH=7.2–7.6]; catalogue number
P4417, Sigma-Aldrich), blocked with 200 μl per well
casein blocking buﬀer (Sigma-Aldrich, catalogue
number B6429) and incubated for 1 h at RT. The
plates were then washed three times with PBSTween-20 (PBS-T; 0.5% Tween-20 in PBS). Serum
samples were pre-diluted 1:400 in casein blocking
buﬀer, then 100 μl per well was added to the ELISA
plate and incubated for 1 h at RT. The wells were
washed three times with PBS-T, then 100 μl of HRPlabelled goat anti-feline IgG (H + L) secondary antibody (ThermoFisher, catalogue number A18757)
diluted 1:2500 was added to each well and incubated
for 1 h at RT. After 1 h, plates were washed ﬁve
times with PBS-T, and 100 μl of TMB ELISA Substrate
Solution (Abcam, catalogue number ab171525,
Cambridge, MA, USA) was added to all wells of the
plate. Following incubation at RT for 5 min, the
reaction was stopped by adding 100 μl Stop Solution
for TMB Substrate (Abcam, catalogue number
ab171529) to all wells. The OD of the ELISA plates
were read at 450 nm on an ELx808 BioTek plate reader
(BioTek, Winooski, VT, USA). The cut-oﬀ for a
sample being called positive was determined as follows: Average OD of negative serum + 3X standard
deviation. Everything above this cut-oﬀ was considered positive.
Gross pathology and histopathology
During postmortem examination, the head including
the entire upper respiratory tract and central nervous system (brain), trachea and lower respiratory
tract, lymphatic and cardiovascular systems, GI
tract and urogenital system, and integument were
evaluated. CSF was collected with a syringe and
needle via the atlanto-occipital (C0-C1) joint.
Lungs were evaluated for gross pathology such as
edema, congestion, discolouration, atelectasis, and
consolidation. Tissue samples from the respiratory
tract, nasal turbinates (rostral and deep), trachea
(multiple levels; Figure S1B) and all 6 lung lobes
(Figure S1C), GI (stomach, small and large intestine) and various other organs and tissues (spleen,
kidney, liver, heart, tonsils, tracheo-bronchial and
mesenteric lymph nodes, brain including olfactory
bulb, and bone marrow) were collected and either
ﬁxed in 10% neutral-buﬀered formalin for histopathologic examination or frozen for RT-qPCR testing. Tissues were ﬁxed in formalin for 7 days, then
were transferred to 70% ethanol (ThermoFisher)
prior to trimming for embedding. Tissues were routinely processed and stained with hematoxylin and
eosin following standard procedures within the histology laboratories of the Kansas State Veterinary
Diagnostic Laboratory (KSVDL) and the Louisiana
Animal Disease Diagnostic Laboratory (LADDL).

Several veterinary pathologists independently examined slides and were blinded to the treatment
groups.
SARS-CoV-2-speciﬁc RNAscope® in situ
hybridization (RNAscope® ISH)
For RNAscope® ISH, an anti-sense probe targeting the
spike (S; nucleotide sequence: 21,563-25,384) of
SARS-CoV-2, USA-WA1/2020 isolate was designed
(Advanced Cell Diagnostics [ACD], Newark, CA,
USA) and used as previously described [23]. Fourmicron sections of formalin-ﬁxed paraﬃn-embedded
tissues were mounted on positively charged Superfrost® Plus Slides (VWR, Radnor, PA, USA). The
RNAscope® ISH assay was performed using the RNAscope 2.5 HD Red Detection Kit (ACD) as previously
described [23,24]. Brieﬂy, deparaﬃnized sections were
incubated with a ready-to-use hydrogen peroxide solution for 10 min at RT and subsequently subjected to
Target Retrieval for 15 min at 98–102°C in 1X Target
Retrieval Solution. Tissue sections were dehydrated in
100% ethanol for 10 min and treated with Protease
Plus for 20 min at 40°C in a HybEZ™ oven (ACD).
Slides were subsequently incubated with a ready-touse probe mixture for 2 h at 40°C in the HybEZ™
oven, and the signal ampliﬁed using a speciﬁc set of
ampliﬁers (AMP 1-6 as recommended by the manufacturer). The signal was detected using a Fast-Red
solution (Red B: Red A in a 1:60 ratio) for 10 min at
RT (RT). Slides were counterstained with 50% Gill
hematoxylin I (Sigma Aldrich) for 2 min, and bluing
performed with a 0.02% ammonium hydroxide in
water. Slides were ﬁnally mounted with Ecomount®
(Biocare, Concord, CA, USA).
SARS-CoV-2-speciﬁc immunohistochemistry
(IHC)
For IHC, four-micron sections of formalin-ﬁxed
paraﬃn-embedded tissue were mounted on positively
charged Superfrost® Plus slides and subjected to IHC
using a SARS-CoV-2-speciﬁc anti-nucleocapsid
mouse monoclonal antibody (clone 6F10, BioVision,
Inc., Milpitas, CA, USA) as previously described
[23]. Brieﬂy, IHC was performed using the automated
BOND-MAX and the Polymer Reﬁne Red Detection
kit (Leica Biosystems, Buﬀalo Grove, IL, USA), as previously described [24]. Following automated deparaﬃnization, heat-induced epitope retrieval (HIER)
was performed using a ready-to-use citrate-based solution (pH 6.0; Leica Biosystems) at 100°C for 20 min.
Sections were then incubated with the primary antibody (diluted at 1 μg/ml in Antibody Diluent [Dako,
Carpinteria, CA]) for 30 min at RT, followed by a
polymer-labeled goat anti-mouse IgG coupled with
alkaline phosphatase (30 min; Powervision, Leica
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Biosystems). Fast Red was used as the chromogen (15
min), and counterstaining was performed with hematoxylin. Slides were mounted with a permanent
mounting medium (Micromount®, Leica Biosystems).

Results
SARS-CoV-2-infected cats remain subclinical
Body temperature and clinical signs were recorded
daily. No remarkable clinical signs were observed
over the course of the study. Body temperatures of
principal and sentinel cats remained mostly within
normal range, except for the principal infected cats
at 2 DPC [Figure S2A]. Body weights of all cats
increased throughout the study as expected for
young animals without clinical disease [Figure S2B].
Complete blood counts and serum biochemistry
were performed on days −1, 1, 3, 5, 7, 10, 14, and 21
DPC for the principal infected cats, and 0, 2, 4, 6, 9,
13 and 20 days post co-mingling (DPCo) for the sentinels. Overall, no signiﬁcant changes in most blood
cell parameters or serum biochemistry were observed.
White blood cell (WBC) counts remained within normal limits for most animals during the course of the
study. No signiﬁcant changes were observed in
serum biochemical analytes except elevated alkaline
phosphatase (ALP) levels in many animals starting at
5 DPC in the sentinels and after 7 DPC in the principal
infected animals [Figure S2C], which might indicate
growth of subadult animals.

SARS-CoV-2 RNA found throughout the
respiratory tract
SARS-CoV-2 RNA was detected in nasal swabs of the
principal infected cats at 1 through 10 DPC (Figure 2
(A)). The nasal swabs of contact animals became RNA
positive for SARS-CoV-2 starting at day 2 DPCo (i.e. 3
DPC) and remained positive up to 9 DPCo (Figure 2
(A)). The oropharyngeal swabs were RNA positive starting at 1 DPC through 10 DPC for the principals and 2
DPCo through 4 DPCo for the sentinels (Figure 2(B)).
Viral RNA was also detected in respiratory tract tissues in principal infected animals (Figure 2(D,E)).
Fresh tissues collected during postmortem examination from the nasal cavity, trachea, bronchi and all
lung lobes were RNA positive for all animals at 4
and 7 DPC (Figure 2(D,E)). Viral RNA levels in the
lungs tended to be lower than the upper respiratory
tract for cats necropsied at 7 DPC (Figure 2(E)). At
21 DPC viral RNA was detected within the upper respiratory samples, as well as bronchi and the right caudal and left cranial lung lobes (Figure 2(D,E)). Nasal
washes and BALF collected at necropsy from all principal infected cats examined at 4 and 7 DPC were RNA
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positive, but negative from the cat evaluated at 21 DPC
(Table 1).
Gross pathology of the respiratory tract was
assessed during postmortem examination for each animal at 4, 7 and 21 DPC and demonstrated various
degrees and distribution of edema, discolouration,
congestion and atelectasis (data not shown). Histologically, the pathological changes were limited to
the upper and lower airways (larynx, trachea, and
main, lobar and segmental bronchi of the lungs) of
SARS-CoV-2 principal infected cats. Pathological
ﬁndings are characterized by multifocal lymphocytic
and neutrophilic tracheobronchoadenitis of seromucous glands of the lamina propria and submucosa of
the trachea and bronchi. Changes range from minimal
to mild at 4 DPC and progress to mild to moderate by
7 DPC (Figure 3, Figure S3). Aﬀected submucosal
glands and associated ducts were variably distended,
lined by attenuated epithelium, and contain necrotic
cell debris. More severely aﬀected glands are poorly
delineated, and disrupted by mild to moderate numbers of inﬁltrating lymphocytes, macrophages and
plasma cells, and few neutrophils (Figure 3, Figure
S3). No signiﬁcant pathology was identiﬁed elsewhere
in the pulmonary parenchyma of SARS-CoV-2infected cats on 4 and 7 DPC. No signiﬁcant histologic
changes were noted in the respiratory tract at 21 DPC,
with the submucosal architecture of the trachea and
bronchi being unremarkable and within normal limits
(Figure 3, Figure S3).
The cellular tropism, distribution and abundance of
SARS-CoV-2 were also investigated via the detection
of viral RNA and viral antigen by RNAscope® ISH
and IHC, respectively. Presence of viral RNA and antigen correlated with the histological changes observed
in the airways and were detected within epithelial
cells of submucosal glands and associated ducts at 4
and 7 DPC (Figure 4, Figure S4). SARS-CoV-2-positive submucosal glands were more frequently observed
at 4 DPC compared to 7 DPC but not at 21 DPC
(Figure 4, Figure S4). No viral RNA or antigen were
detected within lining epithelial cells or elsewhere in
the pulmonary parenchyma, including smaller airways
and alveoli, at 4, 7 or 21 DPC.
SARS-CoV-2 RNA found throughout nonrespiratory organs and tissues
SARS-CoV-2 RNA was detected in rectal swabs starting at 3 DPC for principal infected cats and 2 DPCo
for sentinel cats and were found positive up to 14
DPC/13 DPCo (Figure 2(C)). Urine collected directly
from the bladder during postmortem examination of
cats sacriﬁced at 4, 7, 21 DPC was negative by RTqPCR (Table 1). Viral RNA was detected in the GI
tract and other organs and tissues in principal infected
animals (Figure 2(F,G)). Tonsils, lymph nodes and
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Figure 2. Shedding and presence of SARS-CoV-2 RNA in tissues. RT-qPCR was performed on nasal (A), oropharyngeal (B) and rectal
swabs (C) collected from principal infected and sentinel cats over the course of the 21-day study, as well as, on the upper respiratory tract (D), lower respiratory tract (E), lymphatic (F) and other various tissues (G) from principal infected cats necropsied at 4, 7
and 21 days post challenge (DPC). Average viral copy number (CN) per mL or per mg tissues are shown. Astrisks (*) indicate 1 out
of 2 of the RT-qPCR reactions were below the limit of detection. LN = lymph node; GI = gastrointestinal.

olfactory bulbs of all cats were positive on 4, 7, and 21
DPC with the highest RNA levels detected in the tonsils and lymph nodes. Spleen was negative on 4 DPC,
but positive on 7 and 21 DPC. RNA was present in the
pooled tissue from the GI tract and heart in all animals
on 4 and 7 DPC. Liver, heart, kidney, and bone marrow were occasionally positive on diﬀerent DPC.
CSF was positive from 1 of the 2 cats necropsied at 4
DPC and 1 of 2 cats necropsied at 7 DPC, but not at
21 DPC (Figure 2(G), and Table 1). Blood from all
cats collected at −1, 1, 3, 5, 7, 10, 14 and 21 DPC
was negative for SARS-CoV-2 RNA. Gross and histopathological evaluation of the GI tract, the cardiovascular and central nervous system as well as major
Table 1. Viral RNA (copy number/mL) detected in nasal
washes, bronchoalveolar lung ﬂuid (BALF), cerebrospinal
ﬂuid (CSF) and urine.
Cat ID#

DPC

Nasal washes

476
4
493
4
310
7
597
7
026
21
ND = not determined;

BALF

CSF

visceral organs and lymphoid tissues revealed no
pathological changes at any DPC.
Seroconversion of cats after SARS-CoV-2
infection
Sera at diﬀerent DPC was tested for the presence of
SARS-CoV-2 speciﬁc antibodies. Virus neutralizing
antibodies were detected in sera from all principal
infected and sentinel cats at 7 (not sentinel), 10, 14
and 21 DPC, with neutralizing titres ranging from
1:20 to 1:320 (Table 2). Antibodies against the N
protein were detected in principal cats starting at 5
DPC and in the two sentinels at 13 DPCo (Table 2).
Similarly, antibodies against RBD protein were
detected in principal cats at starting at 5 DPC and in
the sentinels starting at 13 DPCo.

Urine

6.5E+08
5.9E+08
2.5E+04*
ND
7.5E+08
3.2E+08
ND
ND
6.3E+07
2.0E+08
3.6E+06
ND
5.6E+07
4.6E+05
ND
ND
ND
ND
ND
ND
*1/2 RT-qPCR reactions below limit of detection.

Discussion
In this study, we explored in-depth the infection,
associated disease and transmission dynamics in 4–
5-months old domestic cats. While the minimum
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Figure 3. Histopathology of bronchi. Histological ﬁndings in the main bronchi of mock (A) and SARS-CoV-2 experimentally
infected (B-D) cats. Histologic changes and their progression are similar to those observed in the trachea, with multifocal, widespread, mild to moderate lymphocytic and neutrophilic adenitis noted at 4 DPC (B) and 7 DPC (C). Necrotic debris within distorted
submucosal glands are indicated with arrowheads (C), and few transmigrating lymphocytes are indicated with an arrow (B). No
histologic changes are noted at 21 DPC (D). H&E. Total magniﬁcation: 200X.

infectious dose of SARS-CoV-2 for humans, cats or
other susceptible animals is not currently known, in
our study we administered a relatively high infectious
dose via multiple natural infection routes, to achieve
suﬃcient virus exposure for primary infection. Compared to the SARS-CoV-2 study in cats by Shi and colleagues (2020), we used a 1 log higher infectious dose
administered orally and intranasally simultaneously.
The detection of high levels of viral RNA from swab
samples and in various organs and tissues, along
with mild to moderate histologic changes in trachea
and bronchi associated with viral RNA and antigen,
and the development of SARS-CoV-2-speciﬁc antibodies demonstrates that cats were productively
infected, without developing any obvious clinical
signs. Furthermore, the principal infected cats were
able to transmit the virus to sentinel animals within 2
days of contact housing similar to previous reports
[20,25]. Shedding of virus through the respiratory and
GI tract are most likely responsible for the transmission
to the sentinel animals. Shi and coworkers (2020) determined that airborne transmission of SARS-CoV-2
among cats is possible but not highly eﬀective.
Our and previous results [20,25], as well as reports
of cats in households with COVID-19 patients [18,19]
show that felines are susceptible to SARS-CoV-2 infection and could be potential virus reservoirs. Consistent
with our results, previous studies [20,25] also reported
no obvious clinical signs in SARS-CoV-2 infected cats

which were older than 4 months. We detected high
viral RNA levels in many tissues tested at 4 and 7
DPC, with reduced levels (upper respiratory tract,
lymphoid tissues, CNS) or clearing by 21 DPC. Since
no virus was detected in blood, it remains to be studied
how the virus reaches and infects non-respiratory tissues including the CNS. Shi and colleagues [20]
detected viral RNA and infectious virus throughout
upper and lower respiratory tracts in juvenile (70–
100 days old) and subadult cats (6–9 months old) at
3 DPC, but it was cleared from most lung tissues of
subadult cats by 6 DPC. However, in juvenile cats,
virus was still present at 6 DPC in the lower respiratory tract [20]. In contrast, no virus was detected in
other organs of any of these cats which included
brain, heart, submaxillary lymph nodes, kidney,
spleen, liver, and pancreas at 3 or 6 DPC [20]. Similar
to Shi and colleagues (2020) who detected virus in the
small intestine of most of the animals, we found shedding of viral RNA in rectal swabs up to 14 DPC and in
pooled GI tract tissues on 4 and 7 DPC. In contrast,
Halfmann and coworkers (2020) found all rectal
swabs from 4-5 month old animals to be virus negative. These diﬀerences may be explained by the age
of the cats and and/or diﬀerent virus strains used.
SARS-CoV-2 associated pathological changes in
juvenile and subadult infected cats were reported,
but more severe pathology was found in the juvenile
cats [20].
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Figure 4. SARS-CoV-2 RNA and antigen detection in bronchi. SARS-CoV-2 tropism in bronchi of mock (A and B) experimentally
(C-H) infected cats determined by S-speciﬁc RNAscope® in situ hybridization (Fast Red) and anti-N-speciﬁc immunohistochemistry
(IHC; Fast Red). The viral tropism is limited to glandular and ductular epithelial cells of multifocal, scattered submucosal glands.
Viral RNA is detected within infected cells at 4 days post-challenge (DPC; C and D) and, to a lower degree at 7 DPC (E and F). Few
scattered glandular epithelial cells are positive for SARS-CoV-2 N antigen by IHC (D and F, insets). No viral RNA or antigen is
detected at 21 DPC (G and H). Total magniﬁcation: 100X (A, C, E and G) and 200X (B, D, F, H).

Similarly, our results show that subadult cats had
mild to moderate histologic alterations identiﬁed as
tracheobronchoadenitis within the airways. The
macroscopic lung lesions observed were most likely
due to the euthanasia with barbiturates. Importantly,
all SARS-CoV-2 infected cats (principals and sentinels) in our study mounted an antiviral and neutralizing antibody response during the 21-day observation
period. The development of an early serological

response starting at 5–7 DPC in some of the principal
infected cats could be indicative of the high infectious
dose, compared to sentinels which developed antibodies around 10–14 DPC. Other studies reported
detection of virus-speciﬁc and/or neutralizing antibodies also in all infected animals [20,25]. None of
these studies detected virus or viral RNA in the blood.
Experimental infection of cats with SARS-CoV
[9,10] and SARS-CoV-2 [20] reveal histological
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Table 2. Felines develop SARS-CoV-2 speciﬁc and virus neutralizing antibodies.
Anti-N antibodies
DPC
Principals
310
597
026
328
Sentinels
272
903

Anti-RBD antibodies

Virus neutralizing antibodies

5

7

10

14

21

5

7

10

14

21

5

−
−
+
−

−
−
+
+

NA
NA
+
+

NA
NA
+
+

NA
NA
+
NA

−
−
−
+

−
−
+
+

NA
NA
+
+

NA
NA
+
+

NA
NA
+
NA

<1:20
<1:20
<1:20
<1:20

−
−

−
+/−

−
+/−

+
+

+
+

−
−

−
−

−
−

−
+

+
+

<1:20
<1:20

7

10

14

21

1:80
1:160
1:80
1:20

NA
NA
1:320
1:160

NA
NA
1:80
1:160

NA
NA
1:40
1:160

<1:20
<1:20

1:160
1:80

1:160
1:160

1:160
1:160

NA = not available; N = nucleocapsid; RBD = receptor binding domain of spike protein; +/− = OD close to cut-oﬀ.

changes within the airways after various DPC. Similarly, our SARS-CoV-2 infection of subadult cats
demonstrated mild to moderate neutrophilic and lymphocytic tracheobronchoadenitis with associated
intralesional detection of viral RNA and viral antigen.
While SARS-CoV antigen was identiﬁed in cat tracheal and bronchial epithelial cells [9,10], we found
that the epithelial cells of trachea and bronchi seem
non-permissive to SARS-CoV-2 replication in subadult cats as demonstrated by the lack of viral RNA
and antigen; this correlated with the absence of histologic alterations on the surface epithelium. These
ﬁndings are in partial disagreement to those of
another recent cat study [20], where mild histologic
alterations in the tracheal lumen and epithelium
were reported in the absence of detectable viral antigen. Interestingly, SARS-CoV-2 infected subadult
cats did not present histological changes within the
small airways or the pulmonary parenchyma consistent with interstitial pneumonia or diﬀuse alveolar
damage, such as inﬂammatory inﬁltrates within
alveoli, intra-alveolar ﬁbrin or hyaline membranes,
or pneumocyte type II hyperplasia. Additionally,
there is no evidence of SARS-CoV-2 infection within
pneumocytes or alveolar macrophages as demonstrated by the absence of viral RNA and antigen.
These ﬁndings correlate with the absence of clinically
evident respiratory disease following experimental
SARS-CoV-2 infection. While a recent study evaluating the susceptibility of juvenile cats to SARS-CoV-2
[20] suggested the occurrence of histologic alterations
in the pulmonary vasculature and alveolar spaces,
none of these changes were noted in our study.
Additional investigations are needed to determine
whether these diﬀerences are due to the breed and
age of the cats, the virus isolate used or other factors.
Together these ﬁndings warrant COVID-19 screening of felines for epidemiological purposes and for
implementation of mitigation strategies; they also
point towards nasal swabs/washes and rectal swabs
as appropriate diagnostic samples. This information
will be important for providing appropriate veterinary
care for infected cats and cats in their surroundings,
for protection of veterinary personnel, animal caretakers and pet owners, and for applying quarantine
measures to prevent transmission between felines,

people and potentially other susceptible animals. The
ease of transmission between domestic cats indicates
a signiﬁcant public health necessity to investigate a
potential human-cat-human transmission chain. It is
also critical that pet owners are educated on the
risks and preventative measures in order to calm
fears and discourage animal abandonment.
Although asymptomatic, cats can be productively
infected and readily transmit SARS-CoV-2 to other
susceptible cats, and thus may serve as potential
models for asymptomatic COVID-19 infections in
humans. Cats could oﬀer a model for testing vaccines
and antiviral candidates for companion animals and
for drugs with a problematic pharmacokinetic proﬁle
in rodents, ferrets or nonhuman primates. However,
a preclinical animal model that mimics the clinical
symptoms and disease observed in severe COVID-19
patients is still needed to improve the evaluation of
vaccines, antiviral drugs and other therapies.
Further research is needed to adapt models to recapitulate severe disease observed in humans. One area
to explore is the eﬀect of age on clinical outcome.
Only cats less than 1-year-old were evaluated in this
and previous studies [20,25]; however, SARS-CoV-2
infection in adult and old cats, and questions regarding re-infection of cats were not explored in these
studies. Recent non peer-reviewed work by BoscoLauth and colleagues (2020) investigated experimental
SARS-CoV-2 challenge and transmission in adult cats
5–8 years old, and re-infection after 28 DPC [26]. That
study demonstrated that adult cats become infected
without clinical signs and with pathology limited to
respiratory airways, can readily transmit the virus to
naïve cats, and appear to be protected from reinfection
[26]. Studies to better understand the mechanisms of
infection and the range of symptoms and pathology
associated with SARS-CoV-2 in various preclinical
models of COVID-19 are critical for the development
of vaccines and treatments for this disease.
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